Glenmark Pharma’s subsidiary opens antibody manufacturing facility in Switzerland

Glenmark Pharmaceuticals’ wholly owned subsidiary, Glenmark Pharmaceuticals S.A (GPSA), has inaugurated new cGMP compliant monoclonal antibody manufacturing facility in La Chaux-de-Fonds, Switzerland. This manufacturing facility supplements Glenmark's existing in-house discovery and development capabilities and will supply material for clinical development. Glenmark Pharma’s Swiss research center, which is an integrated antibody discovery and development unit, has fully developed in-house capabilities and infrastructure for conducting antibody discovery, cell line development, in vitro testing and characterization of antibodies, process development and analytical research. Further, this new facility supplements the research and development capabilities and will facilitate production of clinidal grade material. The facility has been designed for use of single use bioreactor systems and also houses a suite for manufacturing cell banks. The facility is fully compliant with quality, environmental and safety standards for manufacturing clinical trial material. Glenmark’s biologics research center in Switzerland has a robust pipeline of monoclonal antibodies in various stages of development including bio-specific antibodies. The focus for the biologics R&D center is to develop hovel biologic entities for the treatment of pain, inflammatory, oncologic and respiratory conditions. The company currently has 69 employees at its biologic research center.